自2013年起从事伦理审查工作,专注于医学伦理研究及伦理委员会管理工作。熟悉GCP、赫尔辛基宣言等国内、外伦理规范。具备扎实的医学伦理理论功底及项目管理经验。作为核心成员参与我院SIDCER-FERCAP首次认证(2015年)及复核认证(2018年),推动伦理审查体系符合国际标准。2024年参与我院中医药研究伦理审查体系认证工作,完善伦理审查体系建设。负责伦理委员会日常运作。
Since 2013, I have been engaged in ethics review work, specializing in medical ethics research and institutional review board (IRB) management. I am well-versed in both domestic and international ethical guidelines, including GCP (Good Clinical Practice) and the Declaration of Helsinki. With a solid theoretical foundation in medical ethics and extensive project management experience, I contributed as a core team member in my hospital’s SIDCER-FERCAP initial accreditation (2015) and re-certification (2018), ensuring compliance with international ethical standards. In 2024, I participated in the ethics certification for traditional Chinese medicine research, further refining our ethics review system. My responsibilities include overseeing the daily operations of the Ethics Committee.
6
0
0
| 日期 | 时间 | 会场 | Session | 角色 | 讲题 |
|---|---|---|---|---|---|
| 2026-05-30 | 17:30-18:30 | 分会场9(二层,N215会议室) |
2026年质启新阶・研创致远-临床试验高质量发展培训会暨眼科药物/医疗器械临床试验联盟工作会议 |
讨论 | 讨论议题1、下一年度临床试验行业统一共识体系建设规划 2、聚力临床试验质量效能双提升,优化全流程管控与实施路径 3、多中心临床研究的伦理协作审查协议和操作规程 4、多中心临床研究的伦理审查时间线协调与提速策略 |